Boston Scientific recalled the LGX Preconnect with TENACIO Pump on September 11, 2025. The recall affects devices sold in the U.S. and Canada due to inflation and deflation performance issues. Consumers should stop using the device immediately and follow provided instructions.
The potential for devices to experience inflation and/or deflation performance issues or difficulties.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Boston Scientific Corporation or your healthcare provider for instructions. Notification method: Letter
The recalled products include LGX Preconnect with TENACIO Pump, UPNs: 72404405 (12CM IP) and 72404407 (18CM IP). These devices have UDI-DI numbers 00191506021252 and 00191506021276. The devices were distributed worldwide, including the U.S. and Canada.
The devices may experience inflation and deflation performance issues, which can pose significant health risks. This recall is classified as Class II, indicating a high hazard level.
No specific incidents have been reported, but the potential for complications exists. The recall addresses safety concerns related to device performance.
Patients and healthcare providers should stop using the device immediately. Contact Boston Scientific Corporation or your healthcare provider for further instructions.
For more information, visit Boston Scientific's recall page or call their customer service. More details are available at the FDA's enforcement report.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.